Skip to content
The Policy VaultThe Policy Vault

Qudexy XRBlue Cross Blue Shield of Kansas

Lennox-Gastaut Syndrome

Initial criteria

  • 1. ONE of the following:
  • A. The patient has a diagnosis of migraine OR
  • B. ONE of the following:
  • 1. The patient has ONE of the following diagnoses: Partial onset seizures OR Primary generalized tonic-clonic seizures OR Lennox-Gastaut Syndrome OR
  • 2. The patient has a medication history of use of an anti-seizure medication that is not topiramate OR
  • C. The patient has another FDA labeled indication for the requested agent and route of administration OR
  • D. The patient has another indication that is supported in compendia for the requested agent and route of administration AND
  • 2. If the patient has an FDA labeled indication, then ONE of the following:
  • A. The patient’s age is within FDA labeling for the requested indication for the requested agent OR
  • B. There is support for using the requested agent for the patient’s age for the requested indication AND
  • 3. The patient does NOT have any FDA labeled contraindications to the requested agent

Reauthorization criteria

  • 1. The patient has been previously approved for the requested agent through the plan’s Prior Authorization process AND
  • 2. ONE of the following:
  • A. The patient has had clinical benefit with the requested agent OR
  • B. The patient has a medication history of use of an anti-seizure medication that is not topiramate AND
  • 3. The patient does NOT have any FDA labeled contraindications to the requested agent

Approval duration

12 months